Acadia Pharmaceuticals (ACAD) Stock Explodes 26% After Patent Court Victory

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) stock jumped 26.6% to $22.29 on Friday afternoon following a favorable court ruling.

What To Know: The U.S. District Court for the District of Delaware upheld the validity and found infringement of Acadia's ‘721 formulation patent for NUPLAZID (pimavanserin), a treatment for Parkinson’s Disease Psychosis.

The decision protects the 34 mg capsule formulation from generic competition until 2038, blocking challenges from Aurobindo Pharma and other generic drugmakers.

Acadia CEO Catherine Owen Adams praised the ruling as a major win, emphasizing the company's commitment to protecting innovations that address serious unmet medical needs.

Read Also: Adobe Shares Climb As Short Interest Drops And Technicals Improve: What’s Going On?

How To Buy ACAD Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in ACADIA Pharmaceuticals’ case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

According to data from Benzinga Pro, ACAD has a 52-week high of $25.23 and a 52-week low of $13.40.